Streetbeat News

Earnings

CHH

Choice Hotels Intl (NYSE:CHH) reported Q2 2024 earnings of $1.84 per share, missing the analyst estimate of $1.86. Sales were $435.156 million, also below the $438.232 million estimate. Despite the misses, both earnings and sales showed year-over-year growth.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 10:32 am

COMM

CommScope Holding Company reported its Q2 2024 adjusted EPS of $0.34, significantly beating the estimate of $(0.01). The company's sales also surpassed expectations, coming in at $1.387 billion compared to the estimated $1.228 billion.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 10:31 am

HBI

Hanesbrands (NYSE:HBI) reported Q2 2024 adjusted EPS of $0.15, beating the analyst estimate of $0.10 by 50%. However, sales were $995 million, missing the $1.357 billion estimate by 26.65% and showing a 30.85% decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 10:31 am

LPCN

Lipocine (NASDAQ:LPCN) reported Q2 2024 GAAP EPS of $(0.56), beating the $(0.78) estimate, but sales of $89.565K missed the $290.000K estimate.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 10:30 am

ELAN

Elanco Animal Health (NYSE:ELAN) reported Q2 2024 adjusted EPS of $0.30, beating the $0.24 estimate by 25%. However, sales of $1.020 billion missed the $1.156 billion estimate by 11.78%. EPS increased by 66.67% year-over-year, while sales decreased by 3.50%.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 10:30 am

DCBO

Docebo expects Q3 total revenue to be between $54M and $54.2M, surpassing the estimate of $53.68M. The company has revised its total revenue growth outlook from 17.0%-18.5% to 18.0%-19.0%. Subscription revenue is expected to grow faster than overall company revenue, while professional services revenue will decline sequentially from Q2.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 10:21 am

HIMX

Himax Technologies expects a significant decline in Q3 net revenue by 12%-17% QoQ, with estimated net revenue of $235.2M. The company also projects EPADS of $0.015-$0.045, below the $0.09 estimate. Gross margin is expected to be around 30%, depending on the final product mix.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 10:17 am

HAE

Haemonetics has reaffirmed its fiscal 2025 guidance, projecting adjusted earnings per diluted share of $4.45-$4.75, compared to the $4.6 estimate.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 10:17 am

DCBO

Docebo (NASDAQ:DCBO) reported Q2 2024 adjusted EPS of $0.26, beating the $0.13 estimate by 100%. Sales were $53.054M, surpassing the $52.295M estimate and marking a 21.70% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 10:17 am

JXN

Jackson Financial shares are trading higher following the company's Q2 financial results and a $750 million increase in its repurchase authorization.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 10:14 am